NLS Pharmaceutics AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 16.5 million compared to USD 11.95 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1367 USD | +3.25% | +3.01% | -76.83% |
1st Jan change | Capi. | |
---|---|---|
-76.83% | 6.44M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NLSP Stock
- News NLS Pharmaceutics Ltd.
- NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022